As a Free StocksGuide user, you can view scores for all 7,049 stocks worldwide.
10 Analysts have issued a Kezar Life Sciences Inc forecast:
10 Analysts have issued a Kezar Life Sciences Inc forecast:
| Jun '25 |
+/-
%
|
||
| Revenue | - - |
-
|
|
| Gross Profit | - - |
-
|
|
| EBITDA | -76 -76 |
2%
2%
|
|
| EBIT (Operating Income) EBIT | -77 -77 |
1%
1%
|
|
| Net Profit | -72 -72 |
8%
8%
|
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Kezar Life Sciences, Inc. is a clinical-stage biotechnology company, which engages in the development of novel small molecule therapeutics to treat autoimmunity and cancer in South San Francisco, California. Its product pipeline include KZR-616, KZR-261, and KZR-TBD. The company was founded by John Fowler, Christopher J. Kirk, and Jack Taunton on February 20, 2015 and is headquartered in South San Francisco, CA.
| Head office | United States |
| CEO | Christopher Kirk |
| Employees | 55 |
| Founded | 2015 |
| Website | kezarlifesciences.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.


